Atacama Therapeutics, Inc.
AT-5214, a therapeutic compound for acne vulgaris and dermatology conditions
- Sector
- Biotech
- Headquarters
- WELLESLEY, MA
- Latest Form D
- $830K, May 2024
- Total capital
- $830K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $830K
- 1 Form D · last May 2024
- 30 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 4 pending · first 2018
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$830K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David DoveDirectorNamed in SEC Form D filings
- Jonathan ReisDirectorNamed in SEC Form D filings
- Joseph BaronExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 7- PendingDexmecamylamine And Uses ThereofUSPTOApplication 18572977
- GrantedMethod For Treating Hyperhidrosis with Dexmecamylamine.USPTOUS 11,166,922
- GrantedMethod For Treating Hyperhidrosis With Dexmecamylamine.USPTOUS 10,507,190
Show all 7 patent records
- Dexmecamylamine And Uses ThereofJun 20, 2024 · Application 18572977Pending
- Method For Treating Hyperhidrosis with Dexmecamylamine.Nov 9, 2021 · US 11,166,922Granted
- Method For Treating Hyperhidrosis With Dexmecamylamine.Dec 17, 2019 · US 10,507,190Granted
- Method For Treating Hyperhidrosis With DexmecamylamineSep 25, 2018 · US 10,080,726Granted
- Dexmecamylamine And Uses ThereofApplication 63214567Pending
- Dexmecamylamine And Uses ThereofApplication PCTUS2022034932Pending
- Method For Treating HyperhidrosisApplication PCTUS2015046055Pending
Related companies, and why
- BIOKIER, INC.Similar federal contract value in Biotech · null in contracts
- Breakaway Labs, Inc.Similar federal contract value in Biotech · null in contracts
- Jupiter Biomedical Research, Inc.Similar federal contract value in Biotech · null in contracts
- Nok Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SENTRIMED, INC.Similar federal contract value in Biotech · null in contracts
- Oleander Medical Technologies LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .